Reply to J. Veeck et al

Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457

Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445

Peter C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou, Roger A'Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye, Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Journal of Clinical Oncology. ,vol. 28, pp. 2512- 2519 ,(2010) , 10.1200/JCO.2009.26.9589

Alan Ashworth, A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair Journal of Clinical Oncology. ,vol. 26, pp. 3785- 3790 ,(2008) , 10.1200/JCO.2008.16.0812

Ingrid Hedenfalk, David Duggan, Yidong Chen, Michael Radmacher, Michael Bittner, Richard Simon, Paul Meltzer, Barry Gusterson, Manel Esteller, Mark Raffeld, Zohar Yakhini, Amir Ben-Dor, Edward Dougherty, Juha Kononen, Lukas Bubendorf, Wilfrid Fehrle, Stefania Pittaluga, Sofia Gruvberger, Niklas Loman, Oskar Johannsson, Håkan Olsson, Benjamin Wilfond, Guido Sauter, Olli-P. Kallioniemi, Åke Borg, Jeffrey Trent, Gene-Expression Profiles in Hereditary Breast Cancer The New England Journal of Medicine. ,vol. 344, pp. 539- 548 ,(2001) , 10.1056/NEJM200102223440801

Amir A. Jazaeri, Cindy J. Yee, Christos Sotiriou, Kelly R. Brantley, Jeff Boyd, Edison T. Liu, Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Journal of the National Cancer Institute. ,vol. 94, pp. 990- 1000 ,(2002) , 10.1093/JNCI/94.13.990

N C Turner, J S Reis-Filho, A M Russell, R J Springall, K Ryder, D Steele, K Savage, C E Gillett, F C Schmitt, A Ashworth, A N Tutt, BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. ,vol. 26, pp. 2126- 2132 ,(2007) , 10.1038/SJ.ONC.1210014

Jurgen Veeck, Santiago Ropero, Fernando Setien, Eva Gonzalez-Suarez, Ana Osorio, Javier Benitez, James G. Herman, Manel Esteller, BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.30.1010

Tibor van Welsem, Lodewyk F.A. Wessels, Frans B.L. Hogervorst, Laura J. van't Veer, Peter Devilee, Cees J. Cornelisse, Rogier A. Oldenburg, Petra M. Nederlof, Yunlei Li, Senno Verhoef, Erik H. van Beers, Comparative Genomic Hybridization Profiles in Human BRCA1 and BRCA2 Breast Tumors Highlight Differential Sets of Genomic Aberrations Cancer Research. ,vol. 65, pp. 822- 827 ,(2005)

Timothy A. Yap, Shahneen K. Sandhu, Paul Workman, Johann S. de Bono, Envisioning the future of early anticancer drug development Nature Reviews Cancer. ,vol. 10, pp. 514- 523 ,(2010) , 10.1038/NRC2870